Cargando…
CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
Enzymatic activation of irinotecan (CPT-11) is due to carboxylesterase (CES), and its pharmacological behavior is influenced by drug resistance-related proteins. We previously reported that the clinical response and prognosis of metastatic colorectal cancer (mCRC) patients did not differ in tumors w...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200864/ https://www.ncbi.nlm.nih.gov/pubmed/25198900 http://dx.doi.org/10.3390/ijms150915767 |
_version_ | 1782340119505666048 |
---|---|
author | Silvestris, Nicola Simone, Giovanni Partipilo, Giulia Scarpi, Emanuela Lorusso, Vito Brunetti, Anna Elisabetta Maiello, Evaristo Paradiso, Angelo Mangia, Anita |
author_facet | Silvestris, Nicola Simone, Giovanni Partipilo, Giulia Scarpi, Emanuela Lorusso, Vito Brunetti, Anna Elisabetta Maiello, Evaristo Paradiso, Angelo Mangia, Anita |
author_sort | Silvestris, Nicola |
collection | PubMed |
description | Enzymatic activation of irinotecan (CPT-11) is due to carboxylesterase (CES), and its pharmacological behavior is influenced by drug resistance-related proteins. We previously reported that the clinical response and prognosis of metastatic colorectal cancer (mCRC) patients did not differ in tumors with different thymidylate synthase (TS) or topoisomerase-I (Topo-I) expression. Using immunohistochemistry (IHC), we evaluated the biological role of CES2 and the expression of breast cancer resistance protein (BCRP/ABCG2) in 58 consecutive mCRC patients, who had undergone a first-line CPT-11/5-FU/leucovirin (FOLFIRI) regimen. The expression of these proteins was also examined in a group of synchronous lymph nodes and liver metastases. Furthermore, all samples were revaluated for TS and Topo-I expression. High expression of CES2, ABCG2, TS and Topo-I was observed in 55%, 56%, 38% and 49% of patients, respectively. There was a significant association between high TS and high ABCG2 expression (p = 0.049). Univariate analysis showed that only TS expression significantly impacted on time to progression (p = 0.005). Moreover, Cox’ multivariate analysis revealed that TS expression was significantly associated with overall survival (p = 0.01). No significant correlation was found between investigated markers expression and clinical response. Topo-I expression resulted in being significantly higher in liver metastases with respect to the corresponding primary tumors (p < 0.0001), emphasizing the role of Topo-I expression in metastatic cancer biology. In primary tumor tissues, CES2 expression tended to be higher than that observed in liver metastasis tissues (p = 0.05). These preliminary data may suggest CES2 over-expression as a potential marker of malignant phenotype. In light of these findings, we suggest that Topo-I expression together with TS expression could be associated with metastatic progression of CRC. Further studies are warranted with the aim of evaluating the potential predictive and prognostic role of CES2 and ABCG2 in larger series of patients. |
format | Online Article Text |
id | pubmed-4200864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-42008642014-10-17 CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen Silvestris, Nicola Simone, Giovanni Partipilo, Giulia Scarpi, Emanuela Lorusso, Vito Brunetti, Anna Elisabetta Maiello, Evaristo Paradiso, Angelo Mangia, Anita Int J Mol Sci Article Enzymatic activation of irinotecan (CPT-11) is due to carboxylesterase (CES), and its pharmacological behavior is influenced by drug resistance-related proteins. We previously reported that the clinical response and prognosis of metastatic colorectal cancer (mCRC) patients did not differ in tumors with different thymidylate synthase (TS) or topoisomerase-I (Topo-I) expression. Using immunohistochemistry (IHC), we evaluated the biological role of CES2 and the expression of breast cancer resistance protein (BCRP/ABCG2) in 58 consecutive mCRC patients, who had undergone a first-line CPT-11/5-FU/leucovirin (FOLFIRI) regimen. The expression of these proteins was also examined in a group of synchronous lymph nodes and liver metastases. Furthermore, all samples were revaluated for TS and Topo-I expression. High expression of CES2, ABCG2, TS and Topo-I was observed in 55%, 56%, 38% and 49% of patients, respectively. There was a significant association between high TS and high ABCG2 expression (p = 0.049). Univariate analysis showed that only TS expression significantly impacted on time to progression (p = 0.005). Moreover, Cox’ multivariate analysis revealed that TS expression was significantly associated with overall survival (p = 0.01). No significant correlation was found between investigated markers expression and clinical response. Topo-I expression resulted in being significantly higher in liver metastases with respect to the corresponding primary tumors (p < 0.0001), emphasizing the role of Topo-I expression in metastatic cancer biology. In primary tumor tissues, CES2 expression tended to be higher than that observed in liver metastasis tissues (p = 0.05). These preliminary data may suggest CES2 over-expression as a potential marker of malignant phenotype. In light of these findings, we suggest that Topo-I expression together with TS expression could be associated with metastatic progression of CRC. Further studies are warranted with the aim of evaluating the potential predictive and prognostic role of CES2 and ABCG2 in larger series of patients. MDPI 2014-09-05 /pmc/articles/PMC4200864/ /pubmed/25198900 http://dx.doi.org/10.3390/ijms150915767 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Silvestris, Nicola Simone, Giovanni Partipilo, Giulia Scarpi, Emanuela Lorusso, Vito Brunetti, Anna Elisabetta Maiello, Evaristo Paradiso, Angelo Mangia, Anita CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen |
title | CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen |
title_full | CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen |
title_fullStr | CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen |
title_full_unstemmed | CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen |
title_short | CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen |
title_sort | ces2, abcg2, ts and topo-i primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line folfiri regimen |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200864/ https://www.ncbi.nlm.nih.gov/pubmed/25198900 http://dx.doi.org/10.3390/ijms150915767 |
work_keys_str_mv | AT silvestrisnicola ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT simonegiovanni ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT partipilogiulia ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT scarpiemanuela ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT lorussovito ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT brunettiannaelisabetta ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT maielloevaristo ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT paradisoangelo ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen AT mangiaanita ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen |